Patent ID: 11860163
Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  C | IPC A  G

Claim 0:
1. A method for treating a subject having a cancer, comprising:
(i) (a) determining the level of a bacterium or spores thereof in a sample of the subject;
(b) comparing the level of the bacterium or spores thereof to a reference bacterium or spores thereof level, wherein the reference bacterium or spores thereof level is a level of the bacterium or spores thereof in a patient that had a CAR T cell therapy response;
(c) identifying the subject as likely to have a response to a CAR T cell therapy, or as likely to have no response or a poor response to the CAR T cell therapy, based on the comparison; and
(d) administering the CAR T cell therapy to the subject identified as likely to have a response to the CAR T cell therapy, or administering a therapeutic bacterium or spores thereof or a pharmaceutical comprising thereof to the subject identified as likely to have no response or a poor response to the CAR T cell therapy,
wherein the bacterium is selected from the group consisting of bacteria of the Peptostreptococcaceae family, bacteria of the Bacteroidaceae family, bacteria of the Clostridiaceae family, bacteria of the Lachnospiraceae family, bacteria of the Rikenellaceae family, bacteria of the Lactobacillaceae family, bacteria of the Oscillospiraceae family, bacteria of the Ruminococcaceae family, bacteria of the Acidaminococcaceae family, bacteria of the Peptococcaceae family and combinations thereof; and/or

(ii) (a) determining the level of a bacterial gene in a sample of the subject;
(b) comparing the level of the bacterial gene to a reference bacterial gene level, wherein the reference bacterial gene level is a level of the bacterial gene in a patient that had a CAR T cell therapy response;
(c) identifying the subject as likely to have a response to a CAR T cell therapy, or as likely to have no response or a poor response to the CAR T cell therapy, based on the comparison; and
(d) administering the CAR T cell therapy to the subject identified as likely to have a response to the CAR T cell therapy, or administering a therapeutic bacterium or spores thereof or a pharmaceutical comprising thereof to the subject identified as likely to have no response or a poor response to the CAR T cell therapy,
wherein the bacterial gene is selected from the group consisting of genes involved in vitamin B biosynthesis or secondary bile acid biosynthesis or degradation.